BioSpace News Archive

Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a virtual analyst/investor event and conference call on December 7 at 8:00 AM EDT to discuss the data from two oral presentations and two posters on the MANIFEST clinical trial for CPI-0610 being presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

On December 3 and 4, 2020, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center will host its fifth international symposium on complex arrhythmias, EPLive 2020

Aphex BioCleanse Systems, Inc. (OTCPK: SNST) (“Aphex” or the “Company”), a sanitization solutions company focused on the development and distribution of chemical-free, water-based sanitization and disinfection products trademarked as Hy-IQ® Water, announced today they have filed required financial and disclosure reports with the OTC Pink reporting service for the quarter ending September 30, 2020.

Therap Services, the leading software solution for HIPAA-compliant electronic documentation for LTSS providers, introduces its EVV data integration interface for providers in New York to support the State of New York eMedNY Exchange in an efficient, secure, and legally compliant manner.

Health Union survey highlights perspectives of people living with insomnia and other sleep disorders, supports launch of Sleep-Disorders.net

SHINE Medical Technologies LLC and Von Gahlen International Inc. announced that Von Gahlen will build and install the “supercell,” a bank of 10 hot cells, for SHINE’s U.S. medical isotope production facility in Janesville, Wis.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis)

Viatris Inc. (NASDAQ: VTRS), a new kind of healthcare company, today announced tentative approval from the U.S. Food and Drug Administration (FDA) for a New Drug Application for pediatric dolutegravir tablets for oral suspension, 10 mg.

Abstracts will be presented from the TAK-935/OV935 (soticlestat) clinical development program in Dravet syndrome or Lennox-Gastaut syndrome (Phase 2 ELEKTRA study) and OV101 (gaboxadol) clinical development program in Angelman syndrome (Phase 2 STARS study)

Tarsius Pharma, a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, is pleased to announce that management will participate in the Piper Sandler 32nd Annual Healthcare Conference, being held virtually on November 30th to December 3rd, 2020